Arthneeti
All Q2 FY27 results →
GP

Glenmark Pharmaceuticals Ltd

Q2 FY27Pharmaceuticals & Biotechnology

Glenmark Pharmaceuticals Q2 Results 2026 (FY27) investor presentation: Revenue & Margins

Q2 FY27 investor presentation: what the company reported on revenue, margins and capex.

Price₹2,505
Market cap₹70.7K Cr
P/E22.7
Updated5 Nov 2026
Read2 min read

Get Glenmark Pharmaceuticals Ltd's next results in your feed

Based on Glenmark Pharmaceuticals Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

The short version

Q2 FY27 Revenue:. EBITDA for Q2 FY27: Rs. 8,638 million with a margin of 20.3% (Page 4).

From Glenmark Pharmaceuticals Ltd's Q2 FY27 earnings-call transcript · updated 5 Nov 2026.

How did Glenmark Pharmaceuticals' revenue grow in the September 2026 quarter?

  • Q2 FY27 Revenue:
  • Consolidated Revenue: Rs. 42,473 million, down 29.8% YoY.
  • India: Rs. 13,274 million, up 704.2% YoY (like-for-like growth ~14%).
  • North America: Rs. 12,089 million, down 72.9% YoY (core business YoY growth ~31%).
  • Europe: Rs. 7,920 million, up 6.2% YoY.
  • Emerging Markets: Rs. 8,769 million, up 33.2% YoY.
  • Other Revenue: Rs. 421 million, up 261.0% YoY.
  • H1 FY27 Revenue:
  • Consolidated Revenue: Rs. 82,658 million, down 11.2% YoY.
  • India: Rs. 27,595 million, up 96.4% YoY (like-for-like growth ~15%).
  • North America: Rs. 23,063 million, down 56.0% YoY (core business growth ~25%).
  • Europe: Rs. 15,392 million, up 8.9% YoY.
  • Emerging Markets: Rs. 16,073 million, up 30.6% YoY.
  • Other Revenue: Rs. 536 million, up 192.7% YoY.
  • Outlook:

2 more points from Glenmark Pharmaceuticals Ltd's call on revenue

Create a free account to keep reading this call

What happened to Glenmark Pharmaceuticals' margins in Q2 FY27?

See what Glenmark Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.

What capex is Glenmark Pharmaceuticals planning?

The only related references include: - Enhanced manufacturing and regulatory readiness with U.S. - Plans to launch additional products from Monroe facility in upcoming quarters (Page 8) suggest ongoing capacity utilization but no new capacity creation or expansions are noted.

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
1KRM Ayurveda
Rev 1Mar 1
2Accretion Pha.
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Is Glenmark Pharmaceuticals raising money or cutting debt?

See what Glenmark Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.

How big is Glenmark Pharmaceuticals' order book?

See what Glenmark Pharmaceuticals Ltd said on order book & pipeline — free account, 30 seconds.

Glenmark Pharmaceuticals Ltd — Quarterly revenue & net profit

Revenue Net profit
Mar 2025Q4 FY25
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27

Q2 FY27 figures are not in this chart yet. Latest shown: Jun 2026 (Q1 FY27). The Q2 FY27 numbers from the filing are in the table below.

Glenmark Pharmaceuticals Ltd Q2 FY27 results — key figures

Glenmark Pharmaceuticals Ltd Q2 FY27 reported results vs year-ago quarter, ₹ crore
₹ CrQ2 FY27
Revenue4,157
Operating profit (EBITDA)774
Operating margin18.6%
Profit before tax338
Net profit (PAT)264
EPS (₹)9.35

Source: Glenmark Pharmaceuticals Ltd's results filing to NSE (consolidated), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q1 FY27): revenue ₹4.0K Cr, net profit ₹483 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Glenmark Pharmaceuticals's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Windlas Biotech (Q2 FY27)

    264 Cr, a 19% YoY increase from Rs. Key investor presentation takeaways from Windlas Biotech Ltd's Q2 FY27 investor presentation — and how it ranks against sect

  • Rubicon Research Ltd (Q2 FY27)

    Q2 FY27 revenue from operations: ₹5,764 million, a 39.9% year-on-year increase from ₹4,120 million in Q2 FY26 (Page 6,7,10). Key investor presentation takeaways

  • Blue Jet Health (Q2 FY27)

    Q2 FY27 Revenue from Operations: ₹3,757 million, a 127.1% year-on-year (YoY) increase from ₹1,655 million in Q2 FY26 (Page 13). Key investor presentation takeaw

  • Shilpa Medicare Ltd (Q2 FY27)

    2QFY27 total revenue: INR 538 cr, up 45% YoY (from INR 372 cr in 2QFY26). Key investor presentation takeaways from Shilpa Medicare Ltd's Q2 FY27 investor presen

Compare:vs Sun Pharmaceutical Industriesvs Divis Laboratoriesvs Torrent Pharmaceuticals

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Glenmark Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Glenmark Pharmaceuticals Ltd Q2 FY27 results?

Q2 FY27 Revenue:. EBITDA for Q2 FY27: Rs. 8,638 million with a margin of 20.3% (Page 4).

What is Glenmark Pharmaceuticals Ltd share price analysis?

Glenmark Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 22.7 with a market cap of ₹70,695 Cr. Investors should review the full earnings analysis for detailed insights.

Keep Glenmark Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.